Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02526394
Other study ID # Multiboost
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 2013
Est. completion date March 31, 2017

Study information

Verified date April 2018
Source Public Health England
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial includes groups receiving various combinations of meningitis C and pertussis containing vaccines, to be administered concomitantly in adolescents due their school leaving booster vaccinations (as per UK routine immunisation schedule at 13-17 years of age). Immunogenicity and reactogenicity will be assessed.


Description:

Recent numbers of cases of infection with meningococcal C and pertussis (whooping cough), and the characteristics of the people who are these cases, makes it clear that UK adolescents will require booster doses of vaccination for both in the near future. These are increasingly important priorities for the national immunisation policy advisers to the Department of Health, the Joint Committee on Vaccination and Immunisation (JCVI).

There are good indications that the likely target agegroup for these booster vaccinations will be at 14-17 years. Therefore this study seeks primarily to measure antibody responses to the meningitis C and whooping cough vaccines when given at the same time in this agegroup, and see how well the vaccines are tolerated.

Up to 800 adolescents will be recruited across eight study groups. The eight groups arise as a result of combinations of four meningococcal and two whooping cough vaccines each participant will receive a single dose of each of the two types of vaccine (i.e. two injections). Two blood samples will be collected of 10ml each, one prior to vaccination and the second at 35 weeks later. These samples will allow assessment of how the immune system responds to the vaccinations in terms of the antibodies that are present in the blood.

The study will also be assessing how well the vaccines are tolerated in this age group when given together, as described above. Each participant will therefor be asked to complete a health diary for the week following vaccination. This will record any redness/ swelling/ pain at the injection site as well as any illnesses or visits to a GP or hospital.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date March 31, 2017
Est. primary completion date March 31, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria:

- Participant is willing and able to give written informed consent for participation. If aged below 16 years, parent/legal guardian gives consent while the participant gives written assent for participation in the study.

- Male or female aged 13 years and 6 months (+0 day) to 17 years (+364 days) on the day of consent.

- Completed childhood meningococcal serogroup C and pertussis vaccination according to the UK (catch-up and/or routine) schedule appropriate for the participant's age

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

- Any contraindication to vaccination as specified in the "Green Book"- Immunisation against Infectious Disease.

- Significant illness including progressive neurological disease or seizure disorder; confirmed or suspected immunosuppressive or immunodeficient conditions; major congenital defects; or known bleeding diathesis (or any condition that may be associated with a prolonged bleeding time).

- Any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

- History of invasive meningococcal disease or pertussis.

- Significant contact (household or intimate exposure) to an individual with culture proven Neisseria meningitis disease or pertussis in the previous 60 days.

- Received the routine teenage booster dose of tetanus/diphtheria/polio

- Pregnancy

Temporary Exclusion Criteria

- Fever (sublingual temperature = 38°C)

- Received systemic antibiotic(s) (either oral or parenteral) within the past 7 days. For all visits, if allowed by the study visit window, receipt of systemic antibiotics (either oral or parenteral) will delay venepuncture until at least 7 days after cessation of antibiotics.

- Received any blood or blood products within the past 12 weeks.

- Received another investigational agent within 90 days - or before completion of the safety follow-up period in another study, whichever is longer, prior to enrollment and unwilling to refuse participation in another investigational trial to the end of this study.

- Possibility of pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Meningococcal vaccine
Meningococcal vaccination
Drug:
Pertussis containing vaccine
Pertussis containing vaccination

Locations

Country Name City State
United Kingdom Gloucestershire primary care Gloucestershire
United Kingdom Hertfordshire primary care Hertfordshire

Sponsors (1)

Lead Sponsor Collaborator
Public Health England

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of subjects with serogroup C rabbit serum bactericidal assay (rSBA) titres = 8 and = 128 and rSBA geometric mean titre (GMTs) (and percentage with = 4 fold rise compared to baseline). response to meningococcal vaccination Day 28 following vaccination
Primary Pertussis antigen-specific antibody geometric mean concentration (GMCs) in IU/mL for pertussis toxin (PT), Pertactin, and filamentous haemaglutinnin (FHA) and in U/ml for fimbreal antigens (Fims) 2 and 3 response to pertussis vaccination Day 28 following vaccination
Secondary Tetanus -specific IgG GMCs in IU/mL and percentages above 0.1 IU/mL response to tetanus vaccination Day 28 following vaccination
Secondary Heamophilus type b (Hib)-polyribosylribitol phosphate(PRP)-specific IgG GMCs and proportions achieving IgG concentrations of =0.15 or =1.00 µg/ml response to Hib vaccination Day 28 following vaccination
Secondary Diphtheria-specific IgG GMCs in IU/mL and percentages above 0.1 IU/mL response to diphtheria vaccination Day 28 following vaccination
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Completed NCT02453048 - Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine Phase 1
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01689324 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents Phase 1/Phase 2
Completed NCT01214889 - Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. Phase 3
Completed NCT00804284 - Database Surveillance Safety Study of PENTACEL® Vaccine N/A
Completed NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Phase 3
Completed NCT00534833 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Phase 3
Completed NCT00524732 - Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age N/A
Completed NCT00772369 - Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Phase 4
Completed NCT01457495 - Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly Phase 2
Completed NCT01267058 - Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults Phase 3
Completed NCT00004800 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines Phase 3
Completed NCT02858440 - A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Phase 3
Recruiting NCT04023929 - Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody Assays
Completed NCT02946190 - The PertADO Geneva Trial Phase 2
Completed NCT03541499 - Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults Phase 2
Completed NCT02587520 - Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Phase 1/Phase 2
Completed NCT04589312 - Maternal Pertussis Wholecell Responses Phase 2
Completed NCT02274285 - DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants Phase 3